A Clinical Study on Efficacy & Safety Profile of Propionyl-L-carnitine Tablets for Peripheral Arterial Diseases (PLC)
A Randomized, Multi-centre, Double-blind and Placebo Controlled Clinical Study of the Propionyl-L-carnitine Hydrochloride Tablets
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100053
- Xuanwu Hospital Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The variability between the two standardized claudication tests during the wash-out period must be <20%, as assessed by the formular: (Highest MWD-Lowest MWD)/(Lowest MWDxx100%)
- At the last visit during the wash-out period, the ABI at rest must be ,0.9
Exclusion Criteria:
- with rest pain, ulceration, and/or gangrene
- PAD of a non-atherosclerotic nature
- Aortic or lower extremity arterial surgery, angioplasty, or lumbar sympathectomy within 6 months; any above ankle level amputation. Any type of major surgery during the last three months.
- Except PAD, any concomitant disease that can limit patients' performance in the treadmill exercise.
- with angina (at rest or activity) or any symptom which is sufficiently severe to discontinue the treadmill exercises.
- Myocardial infarction within 6 months
- Severe cerebral dysfunction
- Type I diabetes (Stable type II diabetes can also be included)
- alcohol or drug abused history within 3 months
- Medium or severe anaemia (Hb,90g/L)
- Platelets <100 x 10 9/L
- Bleeding diathesis
- Renal insufficiency or hepatic function laboratory test result>1.5 normal value
- Treatment with LC or carnitien derivatives in the past 3 months
- Pregnancy, lactation, fertility without adequate protest against pregnancy
- Reject to sign the informed consent form
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To compare the difference between pre-and post-the treatment of each group
Time Frame: 4 months
|
4 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Statistically describe the variance of ABI, CT and other indexes at the end of 4th month
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jianxin Li, MD, Xuanwu Hospital, Beijing
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PLC-LZ00108
- SFDA-2006L03870
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.